펜톡시필린
펜톡시필린은 독특한 혈액유변학적 및 면역조절 특성을 지닌 합성 **메틸잔틴 유도체**(테오필린 및 카페인과 구조적으로 유사)입니다. * **개**: 주로 **가족성 개 피부근염**, 귓바퀴 가장자리 지루/괴사, 피부 혈관염(예: 알라바마 롯)과 같이 미세혈관 손상을 동반하는 면역 매개성 피부 질환을 치료하는 데 사용됩니다. 아토피 피부염의 보조 요법으로도 사용되며 확장성 심근병증(DCM)에 대한 연구도 진행 중입니다. * **말**: 피부 혈관염, 내독소혈증, 주상골병, 태반염의 보조 요법으로 사용됩니다. * **고양이**: 고양이 전염성 복막염(FIP)과 관련된 혈관염을 줄이기 위해 프레드니솔론과 함께 사용되기도 합니다. > **임상 팁**: 조직 리모델링 및 염증에 대한 효과가 나타나는 데 시간이 걸리므로 피부 질환의 임상적 이점은 4~8주가 지나야 관찰될 수 있습니다.
작용 기전: The exact mechanisms are multifaceted, combining rheological improvement with anti-inflammatory effects: * **Phosphodiesterase (PDE) Inhibition**: Inhibits erythrocyte PDE → increases intracellular cAMP → increases erythrocyte flexibility and deformability, allowing red blood cells to navigate compromised microvasculature. * **Blood Viscosity Reduction**: Reduces plasma fibrinogen and increases fibrinolytic activity. * **Immunomodulation**: PDE inhibition in leukocytes decreases the production of inflammatory cytokines, notably **TNF-α**, reducing the negative effects of endotoxemia. * **Enzyme Inhibition**: In horses, it acts as a potent inhibitor of **matrix metalloproteinase-9 (MMP-9)** and a modest inhibitor of **MMP-2**, which may aid in preventing tissue degradation.
동물 종별 용량
- Vasculitis (off-label) · 15 mg/kg · PO · q12h · As directed · Rarely used in cats.
- Cutaneous vasculitis / General · 10 mg/kg q12h PO · PO · q12h · 30 days · OK to crush the sustained-release tablets and mix with molasses. If efficacy wanes with time, consider increasing the dose to 15 mg/kg PO twice daily or 10 mg/kg PO three times a day.
- Adjunctive treatment to prevent GI thrombosis · 7.5 mg/kg IV q12 hours · IV · q12h · Can be easily filtered in a 0.5 micron filter for IV use
- To reduce cytokine effects in endotoxemia · 7.5 mg/kg PO q12h · PO · q12h · Efficacy may be improved if used with flunixin
- To reduce cytokine effects in endotoxemia · 8 mg/kg PO q8h · PO · q8h
- Adjunctive treatment (experimental) of sepsis in foals · 7.5 mg/kg IV bolus, followed by a CRI of 1.5 mg/kg/hour · IV · Bolus then CRI · Has been shown to increase regional blood flow and suppress coagulation.
- Adjunctive treatment of equine pastern dermatitis · 4-8 mg/kg PO q12h · PO · q12h · Add if clinical signs do not resolve after 14 days of topical and other immunomodulating therapy
- To increase oxygenation of placenta in placentitis · 7.5 mg/kg PO q12h · PO · q12h
- To increase the circulation to the podotrochlea · 4.5-7 mg/kg PO three times daily · PO · TID
투여 경로
금기
- Intolerance or hypersensitivity to pentoxifylline or other xanthines (e.g., theophylline, caffeine, theobromine)
- Cerebral hemorrhage
- Retinal hemorrhage
- Hypersensitivity to methylxanthines (e.g., theophylline, caffeine)
- Cerebral or retinal hemorrhage
- Severe hepatic or renal impairment (use with caution)
이상반응
- Vomiting
- Inappetence
- Loose stools
- Excitement
- Nervousness
- Dizziness (humans)
- Headache (humans)
- Erythema multiforme (rare in dogs)
- Transient leukocytosis (horses IV)
- Muscle fasciculations (horses IV)
- Sweating on shoulders/flanks (horses IV)
- Mild increases in heart rate (horses IV)
- Anorexia
- Diarrhea
- Restlessness
- Tachycardia
- Tremors
약물 상호작용
- Antihypertensive drugs · May increase hypotensive effect when used concurrently
- NSAIDs · Controversial in horses; may negate beneficial effects for endotoxemia, though some studies show superior efficacy when used with flunixin
- Platelet-aggregation inhibitors (e.g., aspirin, clopidogrel) · Increased risk for bleeding
- Theophylline · Serum levels of theophylline may be increased when used concurrently · major
- Warfarin · Increased risk of bleeding; use together with enhanced monitoring and caution · moderate
- Ciprofloxacin · May increase pentoxifylline levels · moderate
- Antihypertensives · Potential for additive hypotensive effects · minor
모니터링
- Clinical efficacy (resolution of dermatologic or vascular signs)
- Adverse effects (GI upset, CNS signs)
- Clinical response (resolution of skin lesions/improved blood flow)
- Gastrointestinal tolerance
- Signs of bleeding
과용량
Signs of overdose in humans include **flushing, seizures, hypotension, unconsciousness, agitation, fever, somnolence, GI distress, and ECG changes**. One patient who ingested 80 mg/kg recovered completely. Overdoses should be treated using standard methods of appropriate gut emptying (emesis/lavage) and supportive therapies.
VetSheet 약물 레퍼런스는 면허 수의 전문가를 위한 임상 의사결정 보조 도구이며, 전문적 판단이나 제조사의 최신 라벨을 대신하지 않습니다.